Lower muscle volume, and more fat stored in the muscle, are seen linked to higher risk for disease and comorbidities.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

In July 2025, Janssen Research & Development LLC conducted a study is to evaluate the efficacy of icotrokinra compared to ...

Researchers have found in a new research that deucravacitinib significantly improves joint pain and musculoskeletal symptoms ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

Sun Pharma’s INSPIRE-1 and INSPIRE-2 studies met their primary endpoint at Week 24, with Ilumya 100 mg demonstrating superior ...

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated ...

While IL-17 blocking agents are linked to an increased risk for candidiasis, bimekizumab, which blocks two proteins ...

Juvenile arthritis can impact more than just joints affecting eyes skin and internal organs Learn about its symptoms ...

The Queensland institute that discovered the world’s first cervical cancer vaccine has made a breakthrough that could ...

The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.